AML, LYT-200 and PureTech

PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AML
PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment of acute myeloid leukemia.
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.
PureTech Drug Gets FDA Fast-Track Designation for Leukemia
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid leukemia, as well as a separate fast-track designation for the treatment of recurrent/metastatic head and neck squamous cell carcinomas.
PureTech receives FDA fast track designation for leukemia treatment
(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia. The designation aims to expedite the development and regulatory review of drugs addressing serious conditions with unmet medical needs.
PureTech Says FDA Grants Fast Track Designation For LYT-200 In Acute Myeloid Leukemia
Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted
pharmaphorum1d
PureTech confirms negotiations for a possible Nektar merger
PureTech also has discovery and preclinical-stage candidates in oncology, including anti-Galectin-9 and Delta-1 antibodies for solid tumours. Image by Gerd Altmann from Pixabay Image ...
Business Insider26d
PureTech's Deupirfenidone Shows Positive Results In Slowing Lung Function Decline In IPF Patients
(RTTNews) - PureTech Health plc (PRTC, PRTC.L) announced positive results from the ELEVATE IPF trial. This Phase 2b, randomized, double-blind, active- and placebo-controlled, dose-ranging study ...
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company ...
SourceSecurity23d
PureTech's RDAPSS: Autonomous perimeter surveillance
PureTech Systems Inc., a pioneer in geospatial AI-boosted video analytics for wide-area perimeter and border security, is proud to announce the launch of its Rapid Deploy Autonomous Perimeter ...
news.stocktradersdaily16h
Trading (PRTC) With Integrated Risk Controls
GET MORE AI-GENERATED SIGNALS: January 10, 2025, 20:42 pm ET, BY Rick W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short PRTC slightly under 20.06, target 16.8, stop loss @ 20.12 ...
Business Wire26d
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the ...
The two doses of deupirfenidone were chosen based on PureTech’s Phase 1 data, which showed that a 550 mg TID dose of deupirfenidone provided approximately equivalent drug exposure to pirfenidone ...
PureTech Appoints UBS as UK Corporate Broker
BOSTON, January 06, 2025 -- ( BUSINESS WIRE )-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), is pleased to announce that it has appointed UBS as its UK Corporate Broker ...